We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Cutaneous Leishmaniasis Diagnosed by Press Imprint Smear

By LabMedica International staff writers
Posted on 28 Aug 2014
The diagnostic method of choice for cutaneous leishmaniasis historically has been microscopic demonstration of the parasite and isolation of the protozoa in culture and detection of parasite DNA by molecular diagnostic methods.

However most cases of cutaneous leishmaniasis occur in areas without good health infrastructure where diagnostic laboratory facilities are limited, therefore a rapid, sensitive, and inexpensive test for the diagnosis of the disease is needed for use in rural, resource-limited, endemic settings.

Scientists at the Federal University of Ceará (Fortaleza, Brazil) collected skin biopsy samples from 75 patients with a clinical diagnosis of cutaneous leishmaniasis, from September 2011 to August 2013. More...
Two biopsy samples were taken from the borders of ulcers (lesions) using a 3-mm disposable punch. One biopsy specimen was fixed in 10% formalin and processed for histopathology and the other specimen was used for a Press-Imprint-Smear.

For the imprint, the biopsy sample was put on a glass slide, and another glass slide was used to cover the tissue fragment sandwiched in between. On a firm surface, the tissue fragment between both glass slides was squeezed or squashed. Pressure on the middle of the slides was made, and therefore, the juice and tissue cells were spread on both slides surfaces that were in contact with the sample. Smears were air dried, fixed in methanol, stained with Giemsa, and examined microscopically using a 100 × oil immersion lens.

In 69 (92%) patients, the diagnosis of cutaneous leishmaniasis was confirmed by the identification of amastigotes by one or both methods. In 64 (85.3%) patients, amastigotes were detected by Press-Imprint-Smear. In 33 (44%) patients, amastigotes were detected by histopathology, and in 28 (37.3%) patients, amastigotes were detected by both methods. In 36 (48%) patients, parasites were seen only by Press-Imprint-Smear, and in five (6.7%) patients, parasites were seen only by histopathology. Leishmania (Viannia) braziliensis was the only species in this area.

The authors concluded that the Press-Imprint-Smear method was quicker that the histological method as it only took about an hour and had a much higher sensitivity of 85.3% compared with histology at 44%. Considering its sensitivity, low cost, and simplicity, Press-Imprint-Smear is a valuable tool for diagnosing cutaneous leishmaniasis and potentially, other infectious diseases at the point of care in rural or resource-limited endemic regions. The study was published on August 11, 2014, in the American Journal of Tropical Medicine and Hygiene.

Related Links:

Federal University of Ceará



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.